Quest Diagnostics announced a 7.5% increase in its quarterly dividend to $0.86 per share, marking 15 consecutive years of dividend increases. The company also increased its share repurchase authorization by $1 billion, bringing total available repurchase authority to approximately $1.4 billion.

With 59% of S&P 500 companies reported, Q4 2025 shows 13% EPS growth and 8.8% revenue growth. Big Tech's massive capex spending on AI infrastructure ($185B for Alphabet, $200B for Amazon) has sparked concerns about free cash flow sustainability and SaaS disruption from AI agents. This week's earnings focus shifts to semiconductor and software companies to assess whether AI spending benefits the broader ecosystem or threatens traditional business models.

A comprehensive market research report on over-the-counter and direct-to-consumer infectious disease diagnostics forecasts significant growth through 2029, driven by rapid testing technologies, privacy concerns, and digital accessibility. The report analyzes market trends across 15 countries, covering respiratory, STD, UTI, and other infectious disease testing channels, with profiles of 70+ diagnostic companies.

The global esoteric testing market is projected to grow from $27.52 billion in 2025 to $41.56 billion by 2031 at a 7.11% CAGR, driven by rising chronic disease rates, personalized medicine demand, and liquid biopsy adoption. However, stringent regulatory frameworks and reimbursement pressures pose significant challenges to market expansion.

A consumer analysis examines how Taurus Medical, Inc. operates its telehealth TRT platform, which connects patients with licensed healthcare providers through OpenLoop Healthcare Partners. The analysis details the regulatory framework for testosterone as a Schedule III controlled substance, the three-entity operational structure (platform, providers, pharmacies), laboratory testing partnerships with LabCorp and Quest Diagnostics, and treatment options including injectable testosterone and enclomiphene. The article emphasizes that no prescription is guaranteed and that clinical decisions rest solely with independent licensed clinicians.

The global Non-Invasive Prenatal Testing (NIPT) market is projected to grow at a CAGR of 17.01% from 2024 to 2031, reaching USD 9.83 billion from USD 2.8 billion in 2024. Growth is driven by rising demand for early fetal detection, advancements in next-generation sequencing technology, and increased adoption of safer prenatal testing methods. However, high costs, regulatory hurdles, and limited insurance coverage remain significant market restraints, particularly in emerging markets.

The global autism spectrum disorder diagnostics market is projected to grow from $27.38 billion in 2024 to $43.36 billion by 2034, with a CAGR of 4.7%. Key growth drivers include increasing healthcare expenditure, R&D investments, and government initiatives. The autistic disorder segment will dominate at 52.82% market share, while early intervention services and online pharmacies emerge as fastest-growing segments. Major players include LabCorp, Illumina, and Bio-Rad Laboratories, with Asia Pacific and Western Europe expected to lead regional growth.

Quest Diagnostics announced a quarterly cash dividend of $0.80 per share, payable on January 28, 2026 to shareholders of record on January 13, 2026.

Global fertility test market projected to grow from $7.92 billion in 2025 to $14.74 billion in 2033, driven by lifestyle changes, delayed pregnancies, and increasing infertility rates worldwide.

The U.S. drug screening market is projected to grow from USD 2.70 billion in 2024 to USD 3.84 billion by 2034, with a 3.64% CAGR, driven by rising substance abuse, technological advances, and stringent government regulations.

Quest Diagnostics announced a quarterly cash dividend of $0.80 per share, payable on October 20, 2025, to shareholders of record as of October 3, 2025.

The North American Autoimmune Disease Diagnostics Market is projected to grow from $1.96 billion in 2024 to $3.5 billion by 2033, driven by rising autoimmune disease prevalence, technological advancements, and increased healthcare investments.